8:00 am Coffee & Networking
8:45 am Chair’s Opening Remarks
Novel Combination Therapies to Maximise Anti-Cancer Effectiveness and Tumour Microenvironment Modulation
9:00 am Attacking Solid Tumors and Other Cancers in Combination With Immune Checkpoint Inhibitors
Synopsis
• Phase 2 trial data showing cancer-selective oncolytic immunotherapy
• Advancement of a fully owned CTLA-4 antibody into the clinic after completion of IND-enabling studies are completed
9:30 am Clinical efficacy and immuno-modualtory properties of oncolytic adenovirus ONCOS-102
Synopsis
• ONCOS-102 has demonstrated clinical activity in several solid tumor types, both as monotherapy and in combinations
• Class-leading 35% response rate for ONCOS-102 + pembrolizumab combination in PD1 refractory melanoma
• ONCOS-102 drives profound remodulation of the tumor microenvironment and systemic anti-tumor immunity
10:00 am Tumor Microenvironment Modulation Characterization and Evaluation
Synopsis
• Characterize how the interplay between cancer cells, cancer-associated fibroblasts (CAFs_, cancer-associated adipocytes, and macrophages influences the anti-tumour immune response
• Understand how how metabolic diseases (such as obesity) can shape the tumor microenvironment and alter the sensitivity to viral therapeutics
10:30 am Morning Break & Structured Networking
11.00 am Roundtable Discussions
Attendees rotate around each table spending 10 minutes on each discussion, guided by a moderator
OV Selection and Combination Therapy Considerations
• Should we be selecting an appropriate type of OV depending on the specific combination strategy for each patient?
• This roundtable will aim to discuss what combinations might be more effective with genetically simple and pro-inflammatory viruses, and conversely more complex and slower-replicating viruses.
Conventional Cancer Treatments to Enhance Anti-Tumour Immune Activation
• Are radiotherapy and chemotherapy viable options to combine with OV?
• This roundtable will aim to discuss how the OV-combined tumour immunotherapy can be enhanced according to the tumour location and individual patient progress.
Expanding Our Knowledge of OV-specific Biomarkers
• Can OV-combined immunotherapy be better controlled and improved?
• With biomarkers such as MSI, TMB, and PD-L1 being used successfully to predict and monitor PD-1 blockade therapy, this roundtable will aim to discuss how these biomarkers can be evaluated and how best we can pursue other novel OV-specific biomarkers to improve OV-combined immunotherapy.
Moderated by: Christophe Queva, CSO, Oncorus
Optimising Payload Expression
• What are the best payloads to be expressed by OVs?
• With a lack of studies and research in the real time situation of the tumour micro-environment when the tumour is infected by the virus, this roundtable will discuss how the selection for the most useful and effective payloads should be factored into consideration, and what exactly are the most optimal payloads to achieve optimal anti-cancer effects.
Moderated by: Sharad Sharma, Principal Scientist, NBE Pharmacokinetics, Boehringer Ingelheim
11:50 am Coffee Break
Novel Combination Therapies Continued
12:00 pm Exploring Virotherapy/Immunotherapy Combinations for the Treatment of Glioblastoma
Synopsis
• Investigation of a gene therapy agent based on a non-replicating adenoviral vector to deliver the Herpes virus Thymidine kinase gene to glioblastoma by intratumoral injection
• Our studies have shown that this results in high local IFNg levels, and upregulation of PD-L1 on tumor cells, microglia, and macrophages in the tumor microenvironment
• Combination of immune checkpoint blockade with an anti-PD1 antibody overcomes this potential resistance mechanism and leads to a high cure rate in experimental murine glioblastoma models
• This combination is now being advanced towards Phase I clinical trials in primary glioblastoma
12:30 pm Targeting Extracellular Matrix to Enhance Oncolytic Virus Immunotherapy of Brain Tumors
Synopsis
• Abundant presence of hyaluronan in the tumor microenvironment impacts immune cell distribution
• Hyaluronan degrading oncolytic virus alters the recruitment and phenotypes of immune cells in the tumor microenvironment
• Extracellular matrix modifying oncolytic virus synergizes with immune checkpoint blockade to enhance efficacy
1:00 pm Lunch Break
2:10 pm Structured Networking
2:45 pm Coffee Break
Insights from Within the Clinic: Demonstrating the New Generation of Oncolytic Viruses
3:00 pm Making Immune Cold Tumors Hot by Oncolytic Virotherapy – Preliminary Clinical Results
Synopsis
• Many cancers including pancreatic cancer is commonly unresponsive to immunotherapy due to the “immune cold” tumor microenvironment
• LOAd703 is an oncolytic virus encoding TMZ-CD40L and 41BBL that stimulate immune reactions that attracts T cells
• In this presentation we show preliminary clinical data that LOAd703 can make immune cold tumors hot and share data from our ongoing trials
3:30 pm Examining the Effects of Oncolytic HSV-Infected Glioma Cells to Activate NOTCH
Synopsis
• Understand NOTCH signaling changes upon infection
• Mechanism by which HSV modulates these signaling pathways
• Impact of this signaling change on Tumor microenvironment and on anti-tumor immunity
4:00 pm Clinical Updates On RIVAL-01: An Oncolytic Vaccinia Virus
Synopsis
• Phase 1/2 updates on Turnstone’s vaccinia encoding anti-CTLA4 + Flt3 ligand + IL-12
4:30 pm Clinical Insights into a Next Generation HSV that Maximises Antitumor Potency and Selectivity
Synopsis
• Targeting melanoma with an engineered HSV backbone +GM-CSF + GALV-GP R-
• Clinical developments and future directions will be discussed